Kornimate/medical-research-clean huggingface dataset:
to evaluate the pharmacokinetics and safety of ad-208

Conditions: Androgenetic Alopecia

Summary: to evaluate pharmacokinetics and safety of ad-208.

the purpose is that pharmacokinetics and safety of ad-208 in healthy adult male volunteers are evaluated as compared to avodart soft capsule 0.5mg.

Eligibility criteria:
inclusion criteria: * healthy male adult aged between 19 to 50 at the time of screening visit * weight over 50kg and body mass index (bmi) between 17.5 kg/m2 and 30.5 kg/m2 at the time of screening visit * no evidence of medical symptoms or signs of congenital or no chronic disease exclusion criteria: * if having a clinically significant disease or medical history for blood/tumor, genitourinary systen, liver/biliary system, kidney, respiratory system, alimentary system, endocrine system, immune system, cardiovascular system, nervous system, skin and psychical disorder, etc
a novel application of 2% lidocaine injection for male rigid cycstoscopy-a patient-blinded randomised trial

Conditions: Bladder Cancer

Summary: the goal of this clinical trial is to learn about a novel application of lidocaine injection in male patients who needs rigid cycstoscopy test. the main question it aims to answer is:does new application of lidocaine liquid provide pain relief for patients during cystoscopy? before the cycstoscopy,participants will be randomly divided into three different anesthesia mode groups,namely are group a (intraurethral lidocaine gel alone), group b (intraurethral lidocaine gel + lidocaine 2% injection), and group c (intraurethral lidocaine gel + liquid paraffinl).patients only need to prepare and cooperate according to routine surgical operations，which is group b or group c.

the primary objective of this clinical trial is to investigate the efficacy of a novel application of lidocaine injection in alleviating pain for male patients undergoing rigid cystoscopy procedures. rigid cystoscopy is a common diagnostic examination used to visualize the interior of the bladder and urethra. however, it can be associated with discomfort and pain for patients. the central question driving this study is whether the new application of lidocaine liquid can provide effective pain relief during cystoscopy. to address this question, participants will be randomly assigned to one of three anesthesia mode groups: group a, which will receive intraurethral lidocaine gel alone; group b, which will receive intraurethral lidocaine gel along with lidocaine 2% injection; and group c, which will receive intraurethral lidocaine gel along with liquid paraffin. those assigned to group b or group c will only need to prepare and cooperate according to routine surgical operations. this standardizes the pre-procedural preparation process across the study groups, ensuring consistency in the approach to anesthesia administration. by comparing the pain levels experienced by patients in each group during cystoscopy, the study aims to determine the effectiveness of the new lidocaine application method in providing pain relief. this information will be crucial in improving the patient experience during cystoscopy procedures and potentially optimizing anesthesia protocols for future clinical practice.

Eligibility criteria:
inclusion criteria: * male patients under the age of 50 referred for postoperative cystoscopy for bladder cancer exclusion criteria: - 1. other evident causes contributing to lower urinary tract symptoms, such as obvious glandular cystitis and severe urinary tract infections. 2. excessive prostatic hyperplasia. 3. urethral stricture. 4. a history of prior urethral surgeries. 5. uncontrolled hypertension, cardiac conditions, and chronic obstructive pulmonary disease.
mr evaluation of cerebrospinal fluid (csf) dynamics

Conditions: Hydrocephalus; Alzheimer Disease

Summary: the researchers are trying to test a mr imaging method for detection of cerebral spinal fluid (csf) flow in the brain to help diagnosis and better understand diseases that affect brain function.

the purpose of this research is to figure out if mr imaging can detect movement of csf (fluid around the brain) to help better diagnosis and understand the cause of diseases that affect brain function. we are doing this research study to find out if movement of csf is different between healthy adults and those with a disease that affects brain function.

Eligibility criteria:
inclusion criteria: * a healthy control will be defined as an otherwise healthy person who does not have a medical condition that affects brain function or have problems with concentration, memory, balance, or coordination. * patients who have a suspected diagnosis of altered csf dynamics including but not limited to normal pressure hydrocephalus will be referred to dr. cogswell by their care team to be included in the study. conditions of altered csf dynamics include obstructive and non-obstructive hydrocephalus and may be associated with headaches and/or decreased cognitive function. * similarly, patients with impaired cognitive function including but not limited to alzheimer's disease will be referred to dr. cogswell by their care team to be included in the study. exclusion criteria: * subjects with non-mri compatible devices * required sedation * women who may be pregnant will be excluded. * the first 10 subjects with normal pressure hydrocephalus will not have previously been shunted.
influence of mmp on brain avm hemorrhage

Conditions: Arteriovenous Malformations; Cavernous Angiomas; Brain Aneurysms

Summary: brain vascular malformations, including arteriovenous malformations (avm), cavernous malformations (cvm) and aneurysms, are a source of life-threatening risk of intracranial hemorrhage. the etiology and pathogenesis are unknown. there is no medical therapy presently available. prevention of spontaneous intracerebral hemorrhage (ich) is the primary reason to treat brain vascular malformations. the goal of this study is to: begin pilot studies to lay the groundwork for future clinical trials to develop medical therapy to decrease ich risk. matrix metalloproteinases (mmps) regulate the extracellular matrix in association with various hemorrhagic brain disorders. mmp-9 has been most consistently associated with vascular wall instability and hemorrhagic brain disorders. doxycycline, a non-specific mmp inhibitor, may enhance vascular stability, thus reducing the risk of spontaneous hemorrhage in brain vascular malformations by decreasing mmp-9 activity.

* doses will be randomized by the pharmacy department at ucsf for doxycycline 100 mg/bid and placebo bid. these will be prepared in blister-packs. * depending on enrollment/surgery date, patients will take medication either one to two weeks before surgery. patients will be assigned to a treatment group according to a random table. * each patient will be initially provided with a 1 or 2-week supply of drug in blister packs. the patient will take the final dose of study drug on the morning of surgery. baseline labs will be obtained and then again at time of surgery along with a piece of surgical tissue.

Eligibility criteria:
inclusion criteria: * 13 years or older * female patients of child bearing age using barrier-type birth control * creatinine no greater than 2.0 mg/di * alanine aminotransferase (alt) no greater than 2 times upper limit of normal * wbc count at least 3,800/mm3 * bmi within 50% of normal exclusion criteria: * allergy to tetracycline * unstable medical illness (unstable angina, advanced cancer, etc) over the last 30 days * female patients of child-bearing age not using effective birth control (barrier) * history of vestibular disease (except benign positional vertigo) * history of noncompliance with treatment or other experimental protocols * patients taking other antibiotics * history of systemic lupus erythematosis * patients who are immunocompromised patients with clinically significant hepatic dysfunction
stereotactic radiotherapy for brain metastases

Conditions: Metastasis Brain

Summary: stereotactic radiotherapy is an innovative treatment enabling to target accurately brain metastases. the aim of this study is to evaluate tumoral response and acute and late toxicity of this treatment.


Eligibility criteria:
inclusion criteria: * situation 1: in case of several cerebral metastases. in this case, the maximum of cerebral metastases is 3, and the maximum diameter of the largest can not exceed 3 cm. the other two ones can not exceed 1 cm or even maximum 2 cm in diameter for one of the two. the same principle will remain valid in the presence of 2 metastases. * situation 2: in the case of a single metastasis, the diameter should be a maximum of 3 cm * situation 3: in case of metastasis supposed to be radioresistant (renal adenocarcinoma, sarcoma, melanoma ...), only a single metastasis of not more than 3 cm in diameter will be accepted. a primary resection followed by radiotherapy will be preferred. * situation 4: in case of localization near a structure at risk (contact with anterior optical pathways, central nuclei or the brainstem or localization in these structures), a maximum number of 3 metastases may be accepted. however, that included in or close to the risk structure can not exceed 2 cm in diameter and the other two, located outside a risk structure will have a diameter not exceeding 1 or even maximum 2 cm. * situation 5: single metastasis of maximum 3 cm in a context of re-irradiation, the whole encephalon having already received the dose of 10 x 3 gy or its biological equivalent of dose. * signed informed consent exclusion criteria: * impossibility of performing an mri or a ct-scan of the brain with injection of contrast agent * metastases greater than 3 cm at the start

Keywords: brain metastases stereotactic radiation cyberknife
machine learning-based risk profile classification of patients undergoing elective heart valve surgery

Conditions: Heart Valve Diseases; Surgery--Complications

Summary: machine learning methods potentially provide a highly accurate and detailed assessment of expected individual patient risk before elective cardiac surgery. correct anticipation of this risk allows for improved counseling of patients and avoidance of possible complications. the investigators therefore investigate the benefit of modern machine learning methods in personalized risk prediction in patients undergoing elective heart valve surgery.

the investigators performe a monocentric retrospective study in patients who underwent elective heart valve surgery between january 1, 2008, and december 31, 2014 at our center. the investigators use random forests, artificial neural networks, and support vector machines to predict the 30-days mortality from a subset of demographic and preoperative parameters. exclusion criteria were re-operation of the same patient, patients that needed anterograde cerebral perfusion due to aortic arch surgery, and patients with grown up congenital heart disease.

Eligibility criteria:
inclusion criteria: \* patients who underwent heart valve surgery of any kind between 2008-01-01 and 2014-12-31 were included. exclusion criteria: * re-operation of the same patient * patients that needed anterograde cerebral perfusion due to aortic arch surgery * patients with grown-up congenital heart disease

Keywords: random forests heart valve surgery support vector machines artificial neural networks
a study to evaluate the efficacy and safety of shr-2004 injection in preventing postoperative venous thromboembolism in patients undergoing ovarian cancer surgery

Conditions: Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery

Summary: this study is designed to evaluate the efficacy and safety of shr-2004 injection in preventing postoperative venous thromboembolism in patients undergoing ovarian cancer surgery.


Eligibility criteria:
inclusion criteria: 1. aged ≥ 18 years old on the day of signing the informed consent form; 2. diagnosed as stage iii-iv or recurrent ovarian cancer; 3. have surgical indications and no contraindications to surgery, and voluntarily undergo laparotomy or laparoscopic surgery to treat ovarian cancer; 4. understand the research procedures and methods, voluntarily participate in this trial, and sign the written informed consent form. exclusion criteria: 1. the primary site of the tumor is not the ovary or there is brain metastasis; 2. a history that may increase the risk of bleeding; 3. a history of vte in the past or during screening, or a disease that increases thrombosis tendency such as protein c deficiency; 4. patients with atrial fibrillation requiring anticoagulant treatment or the use of artificial heart valves during screening; 5. acute coronary syndrome within 3 months; 6. poorly controlled hypertension before screening, and uncontrolled hypertension within 6 months severe cardiac arrhythmia; 7. any laboratory test indicator during screening or baseline does not meet the standards in the exclusion criteria; 8. have had a history of adverse reactions or allergies related to rivaroxaban or enoxaparin, such as heparin-induced thrombocytopenia; 9. have used any drugs prohibitedother than investigational drugs within 7 days before screening or plan to use during the study; 10. those who have participated in any drug intervention clinical trial within 1 month before screening, or those who are within 5 half-lives of the investigational drug at the time of screening, whichever is longer; 11. those who are expected to use postoperative neuraxial analgesia; 12. those who are expected to use plantar vein pumps, intermittent pneumatic compression devices, electronic or mechanical muscle stimulators after surgery; 13. other circumstances in which the researcher believes that the subject is not suitable to participate in this trial.
clinical trial comparing continuous versus intermittent hemodialysis in icu patients

Conditions: Acute Renal Failure

Summary: the mortality of acute renal failure (arf) remains to be high (around 60-70%) despite manifold improvements in icu care. at present, it is not clear if the method chosen for renal replacement therapy, i.e. intermittent haemodialysis (ihd) or continuous haemofiltration (cvvh), might impact on the outcome of these patients. for this purpose, a prospective randomised clinical study of the effect of continuous versus intermittent renal replacement therapy on the mortality and outcome of acute renal failure will be performed.

please see above

Eligibility criteria:
inclusion criteria: * all icu patients requiring renal replacement therapy exclusion criteria: * patient denies informed consent * patient not requiring intensive care therapy * kidney transplanted patients * chronic renal failure (serum creatinine \> 3mg/dl)
a study to evaluate the effectiveness of laser-ablated implant-abutments to promote tissue healing

Conditions: Jaw, Edentulous, Partially

Summary: the purpose of this study is to determine which implant-abutment design is more likely to promote early soft-tissue healing processes and/or will enhance longitudinal peri-implant bone and soft-tissue health.

the study will assess the integrity of the peri-implant oral soft-tissue attachment to implant abutments by comparing tissue responses to a laser-ablated implant-abutment and an implant-abutment manufactured with a smooth surface. investigators will assess the initial post-surgical peri-implant attachment-seal and will test whether or not the tissue-abutment interface re-forms with equal integrity when the abutment is removed and replaced with a new abutment. data will include histological, radiographic, clinical, and subjective aesthetics to compare the effectiveness of two abutment designs. both devices are supplied by the biohorizons implant systems inc. of birmingham, alabama; the abutments are analogous in design and material except the test device has a laser-ablated surface and the control abutment is smooth.

Eligibility criteria:
inclusion criteria: 1. at least 19 years old 2. healthy enough to under go treatment 3. have one or more edentulous sites that exhibit adequate natural bone and sufficient keratinized tissue 4. demonstrated willingness to undergo study treatment and to comply with study timeline - exclusion criteria: 1. full edentulism 2. any chronic health condition or medication that in the opinion of the investigators may adversely affect bone healing 3. any indication of an inability to make autonomous decisions -

Keywords: dental implants implant abutments
increasing prep awareness and demand among black cisgender women

Conditions: HIV; PrEP

Summary: this study will develop hiv pre-exposure prophylaxis (prep) awareness materials for and with black cis women and gather feedback on the usefulness of these materials at health care sites. the investigators will also use electronic medical records (emr) to compare the number of black cis women who initiate prep before and after the awareness materials are piloted, at the two partner research sites, howard brown health and planned parenthood of il. additional federally qualified health centers and family planning clinics will review the materials and complete a survey on acceptability.

aim 1. develop digital prep awareness materials to engage black cis women. using human centered design and guided by (capability, opportunity, motivation, behavior; theoretical domains framework)com-b+tdf as a behavior change theory, the investigators will conduct 5 focus groups across two clinical sites with black cis women ages 16 to 40 from high hiv-prevalence areas of chicago (n=120 participants). this iterative process, in collaboration with the hbh communications team and led by an experienced human centered design (hcd) researcher, will lead to the development of digital prep awareness materials that will be piloted online. through qualitative analysis of the focus groups, the investigators will generate knowledge regarding how tdf can be used to understand hiv prevention in this population. aim 2. assess acceptability and feasibility of the prep awareness materials in new fqhc \& family planning clinics in ending the hiv epidemic (ehe) jurisdictions. guided by implementation science frameworks and tools, the investigators will develop a toolkit and survey to accompany pilot distribution. the toolkit will provide guidance on using and adapting the awareness materials, based in the behavior change knowledge developed in aim 1. the survey will assess the acceptability, appropriateness, and feasibility of using the awareness materials, to prepare for further assessment and dissemination. the awareness materials, toolkit, and survey will be distributed locally and outside of illinois, through federally qualified health centers and planned parenthood networks, as well as the third coast center for aids research (cfar) and getting to zero networks, with a target of 20 online surveys collected.

Eligibility criteria:
inclusion criteria: * identify as cis women * identify as black or african-american * self-report not living with hiv * reside in a high hiv incidence neighborhood in chicago * aged 16 to 40, inclusive * able to speak english. exclusion criteria: * unable to provide consent

Keywords: cis women black women
a study to evaluate the mass balance, metabolism, elimination, and drug levels of [14c]-bms-986504 (mrtx1719) in participants with advanced solid tumors with homozygous methylthioadenosine phosphorylase deletion

Conditions: Advanced Solid Tumors With Homozygous MTAP Deletion

Summary: the purpose of this study is to evaluate the mass balance, metabolism, elimination, and drug levels of \[14c\]-bms-986504 (mrtx1719) in participants with advanced solid tumors with homozygous methylthioadenosine phosphorylase deletion.


Eligibility criteria:
inclusion criteria * participants must have an advanced, unresectable, or metastatic solid tumor malignancy with a deletion of the methylthioadenosine phosphorylase (mtap) gene. * participants must have received, be refractory to, be ineligible for, or be intolerant of available standard care for their cancer. exclusion criteria * participants must not have a history of any surgical or medical conditions possibly affecting how the study drug is distributed, broken down (metabolized) and removed (excreted or eliminated) from the body. * participants must not have participated in a clinical study involving a radiolabeled study drug within 12 months prior to admission to the research center. * participants must not have a current or recent (within 3 months of study drug administration) gastrointestinal disease. * other protocol-defined inclusion/exclusion criteria apply.

Keywords: protein arginine methyltransferase (prmt5) methylthioadenosine-cooperative prmt5 inhibitor homozygous methylthioadenosine phosphorylase (mtap) deletion mass balance study metabolism elimination drug absorption distribution excretion radiolabeled absorption, distribution, metabolism, and excretion (adme)
gut microbiota and glioblastoma multiforme prognosis

Conditions: Gut Microbiota, Glioblastoma Multiforme, Microglia, Tumor Related Macrophagocyte, Prognosis

Summary: glioma is the most common primary cancer of the central nervous system, and around 50% of patients present with the most aggressive form of the disease, glioblastoma. conventional therapies, including surgery, radiotherapy, and pharmacotherapy (typically chemotherapy with temozolomide), have not resulted in major improvements in the survival outcomes with only a median survival of around 15 months.the main reason may be related to the highly immunosuppressive tumor microenvironment. in recent years, the microbiome has emerged as a key regulator of not only systemic immune regulation but brain circuitry, neuro-physiology and microglia development. we hypothesized that there is a link between the gut microbiota and the gbm development and evolution through the immune regulation cells (microglia and tumor related macrophagocyte) in the blood circulation to impact the prognosis( pfs and mst) of gbm patients.

we divide the paticipants into three groups. (total number = 200 subjects) 1. radio/chemotherapy group - 80 subjects 2. radio/ without chemotherapy group - 70 subjects 3. healthy volunteer group - 50 subjects after the collection of stools before operation and 3 months after the operaton, we will analyze the composition and distribution of gut microbiota, and compare the results of three experiment groups.then we will followe up the patients and analyze the correlation between gut microbiota and prognosis of gbm.

Eligibility criteria:
inclusion criteria: the participants diagnosed with glioblastoma multiforme by immunohistochemistry and molecular (idh1, 1p19q, tert) diagnosis of who 2016 classification of gliomas. the healthy volunteers. exclusion criteria: 1. no cancer or ibd (inflammatory bowel disease); 2. no history of abdominal surgery; 3. no medication related to gastrointestinal motility within 3 months; 4. no oral antibiotic treatments previous 1 month before neurosurgery operation.